Page last updated: 2024-11-05

troglitazone and Hyperlipoproteinemia

troglitazone has been researched along with Hyperlipoproteinemia in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research Excerpts

ExcerptRelevanceReference
"Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles."1.31[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Demant, T1

Other Studies

1 other study available for troglitazone and Hyperlipoproteinemia

ArticleYear
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
    Fortschritte der Medizin. Originalien, 2001, Volume: 119, Issue:1

    Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria

2001